Literature DB >> 24882277

Do prostate cancer nomograms give accurate information when applied to European patients?

Rafal Turo1, James A Forster, Robert M West, Stephen Prescott, Alan B Paul, William R Cross.   

Abstract

OBJECTIVE: The aim of this study was to validate and compare the performance of preoperative risk assessment tools in a population of men treated with radical prostatectomy at a single European institution.
MATERIAL AND METHODS: Patients were identified from databases of radical prostatectomy between 1996 and 2011 from a single UK centre. Information was obtained on demographics, prostate-specific antigen, staging, biopsy and specimen histopathology, and follow-up. Data were inputted into the Memorial Sloan-Kettering Cancer Center (MSKCC), Partin 1997 and Makarov/Partin 2007 nomograms, and the University of California San Francisco-Cancer of the Prostate Risk Assessment tool (UCSF-CAPRA). The risks of extracapsular extension (ECE), seminal vesicle invasion (SVI) and lymph-node involvement (LNI) were calculated and compared with known outcomes. Nomogram performance was measured using Hosmer-Lemeshow (HL) goodness-of-fit tests, calculating concordance indices (c-indices) and calibration curves.
RESULTS: Data were obtained for 541 patients. Prediction of ECE was relatively poor using all nomograms, with the Makarov/Partin 2007 the most accurate at prediction over the range of risk stratification (HL 9.9, c-index 0.62). Predictions of SVI and LNI were better than for ECE, with the MSKCC nomogram performing best for SVI (HL 10.9, c-index 0.73) and all nomograms performing well for LNI prediction (c-indices 0.8 to 0.815). CAPRA predicted best for SVI (OR 1.49, 95% confidence interval 1.27-1.74).
CONCLUSIONS: To the authors' knowledge, this is the first head-to-head comparison of the accuracy of these commonly used risk calculators in a North European population. Caution should be used when counselling patients using nomograms. Although nomograms may be used as a guide, patients should be warned that they often have not been validated on different European populations and may give misleading information regarding a patient's specific risks.

Entities:  

Keywords:  cancer; nomogram; prostate.

Mesh:

Substances:

Year:  2014        PMID: 24882277     DOI: 10.3109/21681805.2014.920415

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  5 in total

Review 1.  Prognostic Utility of PET in Prostate Cancer.

Authors:  Hossein Jadvar
Journal:  PET Clin       Date:  2015-01-22

2.  Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management.

Authors:  Stefan A Koerber; Gerald Stach; Clemens Kratochwil; Matthias F Haefner; Henrik Rathke; Klaus Herfarth; Klaus Kopka; Tim Holland-Letz; Peter L Choyke; Uwe Haberkorn; Juergen Debus; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-07-13       Impact factor: 11.082

3.  Optimising preoperative risk stratification tools for prostate cancer using mpMRI.

Authors:  Lars A R Reisæter; Jurgen J Fütterer; Are Losnegård; Yngve Nygård; Jan Monssen; Karsten Gravdal; Ole J Halvorsen; Lars A Akslen; Martin Biermann; Svein Haukaas; Jarle Rørvik; Christian Beisland
Journal:  Eur Radiol       Date:  2017-10-06       Impact factor: 5.315

4.  Establishment and Validation of Extra-transitional Zone Prostate Specific Antigen Density (ETzD), a Novel Structure-based Parameter for Quantifying the Oncological Hazard of Prostates with Enlarged Stroma.

Authors:  Jung Jun Kim; Yoon Seok Suh; Tae Heon Kim; Seong Soo Jeon; Hyun Moo Lee; Han Yong Choi; Seonwoo Kim; Kyu-Sung Lee
Journal:  Sci Rep       Date:  2019-01-25       Impact factor: 4.379

5.  Head-to-Head Comparison of Two Nomograms Predicting Probability of Lymph Node Invasion in Prostate Cancer and the Therapeutic Impact of Higher Nomogram Threshold.

Authors:  Zilvinas Venclovas; Tim Muilwijk; Aivaras J Matjosaitis; Mindaugas Jievaltas; Steven Joniau; Daimantas Milonas
Journal:  J Clin Med       Date:  2021-03-02       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.